COVID-19 and the Use of Angiotensin II Receptor Blockers in Older Chronic Hypertensive Patients: Systematic Review and Meta-Analysis
Metadatos
Afficher la notice complèteEditorial
MDPI
Materia
Angiotensin-converting enzyme inhibitors ACEI COVID-19 disease Antihypertensive drugs Older SARS-CoV-2 infection Selective angiotensin II receptor antagonists ARAII
Date
2023-06-26Referencia bibliográfica
Quesada-Caballero, M.; Carmona-García, A.; Chami-Peña, S.; Albendín-García, L.; Membrive- Jiménez, C.; Romero-Béjar, J.L.; Cañadas-De la Fuente, G.A. COVID-19 and the Use of Angiotensin II Receptor Blockers in Older Chronic Hypertensive Patients: Systematic Review and Meta- Analysis. Medicina 2023, 59, 1200. [https://doi.org/10.3390/ medicina59071200]
Résumé
Angiotensin II-converting enzyme inhibitors (ACEIs) and selective angiotensin II receptor
antagonists (ARAIIs) are widely used antihypertensive agents. Their use has generated controversy
due to their possible influence on the health status of chronic patients infected with COVID-19. The
objective of this work is to analyze the influence of COVID-19 on chronic hypertensive patients treated
with ACEI and ARAII inhibitors. A systematic review and meta-analysis in the databases Pubmed,
Pro-Quest and Scopus were carried out. The systematic review was conducted in accordance with
the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The
search equation descriptors were obtained from the Medical Subject Headings (MeSH) thesaurus. The
search equation was: “Older AND hypertension AND (COVID-19 OR coronavirus) AND primary
care” and its equivalent in Spanish. Nineteen articles were obtained, with n = 10,806,159 subjects.
Several studies describe the COVID-19 association with ACEI or ARAII treatment in hypertension
patients as a protective factor, some as a risk factor, and others without a risk association. In the case
of ACEI vs. ARAII, the risk described for the former has an odds ratio (OR) of 0.55, and for ARAII,
an OR of 0.59. Some authors talk about mortality associated with COVID-19 and ACEI with a half
ratio (HR) of 0.97, and also associated ARAIIs with an HR of 0.98. It is recommended to maintain the
use of the renin–angiotensin–aldosterone axis in the context of the COVID-19 disease